Analytical Data
-
Gene name
mrkA
- Application
-
Alternative Names
mrkAFimbrial subunit type 3
-
Species
Klebsiella pneumoniae
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12267
-
Expression Region
23-202aa
-
Molecular Weight
34.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the mrkA recombinant protein is rooted in its significance in microbial pathogenesis, particularly in relation to uropathogenic Escherichia coli (UPEC). MrkA is a key adhesin found on the surface of UPEC, playing a crucial role in biofilm formation and adherence to urinary tract epithelial cells. This ability to adhere is a critical factor contributing to urinary tract infections (UTIs), which are among the most common infections in humans. Understanding the molecular mechanisms by which mrkA facilitates attachment and biofilm development can provide insights into the pathophysiology of UTIs. Moreover, as antibiotic resistance becomes an increasing challenge in treating such infections, mrkA presents a potential target for novel therapeutic strategies. Researchers are interested in producing recombinant mrkA protein to study its structural and functional properties, utilizing techniques such as protein expression systems and purification methods. By characterizing this protein, it may be possible to develop vaccines or inhibitors that can prevent UPEC adherence, thus reducing the incidence of UTIs. The exploration of mrkA not only enhances our understanding of bacterial adhesion but also paves the way for innovative approaches in combating infections caused by resistant bacterial strains.
